Skip to Main Content
Welcome to theĀ Scientist.comĀ Marketplace

Go to Main Navigation

BP6345b

Metabotropic Glutamate Receptor 5 (GPRC1E) Antibody (C-term E1127) Blocking peptide

Abcepta

DETAILS

  • Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
  • Gene Id: 2915
  • Category: Peptides; Blocking Peptides
  • Subtitle: Synthetic peptide
  • Gene Name: GRM5
  • Other Names: Metabotropic glutamate receptor 5, mGluR5, GRM5, GPRC1E, MGLUR5
  • Availability: 2 weeks
  • Bio Background: L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5 (also known as GPRC1E) and these receptors have been shown to activate phospholipase C. Group II includes GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities. The activity of GRM5 is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system and generates a calcium-activated chloride current.
  • Bio References: Pacheco, R., et al., J. Biol. Chem. 279(32):33352-33358 (2004).Anneser, J.M., et al., Neuroreport 15(2):271-273 (2004).Uchino, M., et al., J. Biol. Chem. 279(3):2254-2261 (2004).Corti, C., et al., J. Biol. Chem. 278(35):33105-33119 (2003).Aronica, E., et al., Eur. J. Neurosci. 17(10):2106-2118 (2003).
  • Primary Accession: P41594
  • Targetspecificity: The synthetic peptide sequence used to generate the antibody AP6345b was selected from the C-term region of human GPRC1E. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.